Synthomer (SYNT) Q3 2025 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 TU earnings summary
23 Oct, 2025Executive summary
Q3 2025 performance remained resilient despite ongoing soft demand in several end markets, with Adhesive Solutions leading recovery and margin improvement.
Additional cost-saving and efficiency initiatives helped offset subdued market conditions, including a global workforce reduction of around 250 roles.
Strategic transformation and divestment efforts continued, with a focus on deleveraging and portfolio simplification.
Financial highlights
Continuing Group EBITDA for 2025 is expected to be similar to the £143m reported in 2024.
Anticipated cash inflow in H2 2025 is expected to result in broadly neutral Free Cash Flow for the year.
Outlook and guidance
Persistently soft end-market demand is expected for the remainder of 2025, but self-help actions are expected to largely mitigate the impact.
Full-year 2026 earnings and cash generation are anticipated to improve due to ongoing cost actions and product investments.
Medium-term objective remains to double recent earnings levels through cost actions and a focus on specialty products.
Latest events from Synthomer
- Strong H1 2026 results, upgraded outlook, and deleveraging driven by specialty growth.SYNT
H1 2026 - Strong H1 growth and Q2 momentum support year-on-year progress despite market uncertainty.SYNT
Q2 2026 TU - Margin gains, lower net debt, and strong Q1 2026 momentum support a positive outlook.SYNT
H2 2025 - 2025 guidance reaffirmed; refinancing and divestment progressing, with 2026 trading on track.SYNT
Trading update - Margins improved and cash flow remained positive despite lower revenue in challenging markets.SYNT
Q4 2025 TU - EBITDA and margin gains offset revenue drop; cost cuts and deleveraging remain priorities.SYNT
H1 2025 - Q3 2024 delivered improved volumes and EBITDA, with strategic progress and positive cash flow outlook.SYNT
Trading Update - Revenue, EBITDA, and margins rose in H1 2024, with positive FCF outlook and ongoing transformation.SYNT
H1 2024 - Strong 2024 growth, specialty focus, and positive 2025 outlook despite market headwinds.SYNT
H2 2024